Patents by Inventor James F. Blake

James F. Blake has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • KRas G12D inhibitors
    Patent number: 11964989
    Abstract: Compounds that inhibit KRas G12D. In particular, compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor, and in particular, methods of treating cancer. The compounds have a general structure represented by Formula (I): or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 20, 2022
    Date of Patent: April 23, 2024
    Assignees: Mirati Therapeutics, Inc., Array BioPharma Inc.
    Inventors: Xiaolun Wang, Aaron Craig Burns, James Gail Christensen, John Michael Ketcham, John David Lawson, Matthew Arnold Marx, Christopher Ronald Smith, Shelley Allen, James F. Blake, Mark Joseph Chicarelli, Joshua Ryan Dahlke, Donghua Dai, Jay Bradford Fell, John Peter Fischer, Macedonio J. Mejia, Brad Newhouse, Phong Nguyen, Jacob Matthew O'Leary, Spencer Pajk, Martha E. Rodriguez, Pavel Savechenkov, Tony P. Tang, Guy P.A. Vigers, Qian Zhao, Dean Russell Kahn, John Gaudino, Michael Christopher Hilton
  • Fused heterocyclic compounds as RET kinase inhibitors
    Patent number: 11964988
    Abstract: Provided herein are compounds of the Formula (I): (I) and tautomers, stereoisomers and pharmaceutically acceptable salts and solvates thereof, wherein Rx, Ry, W, X, Y, Z, Ring A and (AA) have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
    Type: Grant
    Filed: September 6, 2019
    Date of Patent: April 23, 2024
    Assignee: ARRAY BIOPHARMA INC.
    Inventors: James F. Blake, Donghua Dai, Julia Haas, Yutong Jiang, Dean Kahn, Gabrielle R. Kolakowski, Elizabeth A. McFaddin, Megan L McKenney, Andrew T. Metcalf, David A. Moreno, Brett Prigaro, Ginelle A. Ramann, Li Ren, Shane M. Walls, Hailong Zhang
  • KRAS G12C INHIBITORS
    Publication number: 20240101553
    Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Application
    Filed: August 4, 2023
    Publication date: March 28, 2024
    Inventors: Matthew Arnold MARX, James Gail CHRISTENSEN, Christopher Ronald SMITH, James F. BLAKE, Laurence E. BURGESS, Mark Joseph CHICARELLI, Adam COOK, Jay Bradford FELL, John P. FISCHER, Macedonio J. MEJIA, Martha E. RODRIGUEZ, Pavel SAVECHENKOV, Tony P. TANG, Guy P.A. VIGERS
  • KRas G12C inhibitors
    Patent number: 11932633
    Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Grant
    Filed: May 6, 2019
    Date of Patent: March 19, 2024
    Assignees: Mirati Therapeutics, Inc., Array Biopharma Inc.
    Inventors: Matthew Arnold Marx, Matthew Randolph Lee, James F. Blake, Mark Joseph Chicarelli, Jay Bradford Fell, John P. Fischer, Erik James Hicken, Pavel Savechenkov, Tony Tang, Guy P. A. Vigers, Henry J. Zecca
  • SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS
    Publication number: 20240066029
    Abstract: Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
    Type: Application
    Filed: June 27, 2023
    Publication date: February 29, 2024
    Inventors: Steven W. ANDREWS, Sean ARONOW, James F. Blake, Barbara J. BRANDHUBER, Adam COOK, Julia HAAS, Yutong JIANG, Gabrielle R. KOLAKOWSKI, Elizabeth A. MCFADDIN, Megan L. MCKENNEY, Oren T. MCNULTY, Andrew T. METCALF, David A. MORENO, Tony P. TANG, Li REN
  • Substituted pyrazolo[1,5-A]pyrazine compounds as ret kinase inhibitors
    Patent number: 11851434
    Abstract: Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X1, X2, X3 and X4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.
    Type: Grant
    Filed: October 29, 2021
    Date of Patent: December 26, 2023
    Assignee: Array BioPharma Inc.
    Inventors: Steven W. Andrews, James F. Blake, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski, David A. Moreno, Li Ren, Shane M. Walls
  • KRAS G12C INHIBITORS
    Publication number: 20230373999
    Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Application
    Filed: October 21, 2022
    Publication date: November 23, 2023
    Inventors: Matthew Arnold MARX, James Gail CHRISTENSEN, Christopher Ronald SMITH, James F. BLAKE, Laurence E. BURGESS, Mark Joseph CHICARELLI, Adam COOK, Jay Bradford FELL, John P. FISCHER, Macedonio J. MEJIA, Martha E. RODRIGUEZ, Pavel SAVECHENKOV, Tony P. TANG, Guy P.A. VIGERS
  • Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
    Patent number: 11648243
    Abstract: Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
    Type: Grant
    Filed: December 1, 2020
    Date of Patent: May 16, 2023
    Assignee: Array Biopharma Inc.
    Inventors: Steven W. Andrews, Sean Aronow, James F. Blake, Barbara J. Brandhuber, James Collier, Adam Cook, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski, Elizabeth A. Mcfaddin, Megan L. Mckenney, Oren T. McNulty, Andrew T. Metcalf, David A. Moreno, Ginelle A. Ramann, Tony P. Tang, Li Ren, Shane M. Walls
  • Protein tyrosine phosphatase inhibitors
    Patent number: 11634417
    Abstract: Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Grant
    Filed: March 31, 2020
    Date of Patent: April 25, 2023
    Assignee: Array BioPharma Inc.
    Inventors: James F. Blake, Mark Laurence Boys, Mark Joseph Chicarelli, Adam W. Cook, Mohamed S. A. Elsayed, Jay Bradford Fell, John P. Fischer, Ronald Jay Hinklin, Yutong Jiang, Oren T. McNulty, Macedonio J. Mejia, Martha E. Rodriguez, Christina E. Wong
  • SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS
    Publication number: 20230090520
    Abstract: Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
    Type: Application
    Filed: November 19, 2021
    Publication date: March 23, 2023
    Inventors: Steven W. ANDREWS, Sean ARONOW, James F. BLAKE, Barbara J. BRANDHUBER, Adam COOK, Julia HAAS, Yutong JIANG, Gabrielle R. KOLAKOWSKI, Elizabeth A. MCFADDIN, Megan L. MCKENNEY, Oren T. MCNULTY, Andrew T. METCALF, David A. MORENO, Tony P. TANG, Li REN
  • Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
    Patent number: 11603374
    Abstract: Provided herein are compounds of the Formula I: [INSERT FORMULA I] and tautomers, stereoisomers and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2 and Ry have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: March 14, 2023
    Assignee: Array BioPharma Inc.
    Inventors: James F. Blake, Donghua Dai, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski, Elizabeth A. McFaddin, Megan L. McKenney, Andrew T. Metcalf, David A. Moreno, Brett Prigaro, Ginelle A. Ramann, Li Ren
  • KRAS G12D INHIBITORS
    Publication number: 20230077225
    Abstract: The present invention relates to compounds that inhibit KRas G12D. In particular, the present invention relates to compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Application
    Filed: July 20, 2022
    Publication date: March 9, 2023
    Inventors: Xiaolun Wang, Aaron Craig Burns, James Gail Christensen, John Michael Ketcham, John David Lawson, Matthew Arnold Marx, Christopher Ronald Smith, Shelley Allen, James F. Blake, Mark Joseph Chicarelli, Joshua Ryan Dahlke, Donghua Dai, Jay Bradford Fell, John Peter Fischer, Macedonio J. Mejia, Brad Newhouse, Phong Nguyen, Jacob Matthew O'Leary, Spencer Pajk, Martha E. Rodriguez, Pavel Savechenkov, Tony P. Tang, Guy P.A. Vigers, Qian Zhao, Dean Russell Kahn, John Gaudino, Michael Christopher Hilton
  • Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors
    Patent number: 11524963
    Abstract: Provided herein are compounds of the Formula I: and tautomers and pharmaceutically acceptable salts and solvates thereof, wherein R1 and R2 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: December 13, 2022
    Assignee: Array Biopharma Inc.
    Inventors: James F. Blake, Donghua Dai, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski, Andrew T. Metcalf, David A. Moreno, Brett Prigaro, Li Ren
  • Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors
    Patent number: 11472802
    Abstract: Provided herein are compounds of the Formula I: and tautomers and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2 and R3 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: October 18, 2022
    Assignee: Array BioPharma Inc.
    Inventors: Shane M. Walls, Li Ren, Ginelle A. Ramann, David A. Moreno, Andrew T. Metcalf, Elizabeth A. McFaddin, Gabrielle R. Kolakowski, James F. Blake, Donghua Dai, Julia Haas, Yutong Jiang, Dean Kahn
  • SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS
    Publication number: 20220313676
    Abstract: Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
    Type: Application
    Filed: December 1, 2020
    Publication date: October 6, 2022
    Inventors: Steven W. ANDREWS, Sean ARONOW, James F. BLAKE, Barbara J. BRANDHUBER, James COLLIER, Adam COOK, Julia HAAS, Yutong JIANG, Gabrielle R. KOLAKOWSKI, Elizabeth A. MCFADDIN, Megan L. MCKENNEY, Oren T. MCNULTY, Andrew T. METCALF, David A. MORENO, Ginelle A. RAMANN, Tony P. TANG, Li REN, Shane M. WALLS
  • KRas G12D inhibitors
    Patent number: 11453683
    Abstract: Compounds that inhibit KRas G12D; in particular, compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor, and in particular, methods of treating cancer. The compounds have a general structure represented by Formula (I): or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 27, 2020
    Date of Patent: September 27, 2022
    Assignees: MIRATI THERAPEUTICS, INC., ARRAY BIOPHARMA INC.
    Inventors: Xiaolun Wang, Aaron Craig Burns, James Gail Christensen, John Michael Ketcham, John David Lawson, Matthew Arnold Marx, Christopher Ronald Smith, Shelley Allen, James F. Blake, Mark Joseph Chicarelli, Joshua Ryan Dahlke, Donghua Dai, Jay Bradford Fell, John Peter Fischer, Macedonio J. Mejia, Brad Newhouse, Phong Nguyen, Jacob Matthew O'Leary, Spencer Pajk, Martha E. Rodriguez, Pavel Savechenkov, Tony P. Tang, Guy P. A. Vigers, Qian Zhao, Dean Russell Kahn, John Gaudino, Michael Christopher Hilton
  • HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS
    Publication number: 20220226326
    Abstract: The present invention provides compounds, including resolved enantiomers, resolved diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula I: Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
    Type: Application
    Filed: August 23, 2021
    Publication date: July 21, 2022
    Applicants: Array BioPharma Inc., Genentech, Inc.
    Inventors: Ian S. Mitchell, James F. Blake, Rui Xu, Nicholas C. Kallan, Dengming Xiao, Keith Lee Spencer, Josef R. Bencsik, Eli M. Wallace, Stephen T. Schlachter, Anna L. Leivers, Jun Liang, Brian Safina, Birong Zhang, Christine Chabot, Steven Do
  • SUBSTITUTED PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS
    Publication number: 20220119396
    Abstract: Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X1, X2, X3 and X4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.
    Type: Application
    Filed: October 29, 2021
    Publication date: April 21, 2022
    Inventors: Steven W. ANDREWS, James F. BLAKE, Julia HAAS, Yutong JIANG, Gabrielle R. KOLAKOWSKI, David A. MORENO, Li REN, Shane M. WALLS
  • FUSED HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS
    Publication number: 20220112214
    Abstract: Provided herein are compounds of the Formula (I): (I) and tautomers, stereoisomers and pharmaceutically acceptable salts and solvates thereof, wherein Rx, Ry, W, X, Y, Z, Ring A and (AA) have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
    Type: Application
    Filed: September 6, 2019
    Publication date: April 14, 2022
    Inventors: James F. BLAKE, Donghua DAI, Julia HAAS, Yutong JIANG, Dean KAHN, Gabrielle R. KOLAKOWSKI, Elizabeth A. MCFADDIN, Megan L. MCKENNEY, Andrew T. METCALF, David A. MORENO, Brett PRIGARO, Ginelle A. RAMANN, Li REN, Shane M. WALLS, Hailong ZHANG
  • SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES
    Publication number: 20220081438
    Abstract: Provided herein are compounds of the general Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which Ring A, Ring B, Ring C, R1, R2, L, Y, and W have the meanings given in the specification, which are inhibitors of FGFR1, FGFR2, FGFR3 and/or FGFR4 and are useful in the treatment and prevention of diseases which can be treated with an FGFR inhibitor, including diseases or disorders mediated by FGFR1, FGFR2, FGFR3 and/or FGFR4.
    Type: Application
    Filed: December 13, 2019
    Publication date: March 17, 2022
    Inventors: James F. Blake, David A. MORENO, Li REN, Tony P. TANG, Shane M. WALLS